Summary
MUC2 — the dominant secreted mucin in the colon — is not protein with sugar attached. It is, by weight, mostly sugar. Up to eighty percent of the molecule's mass is its O-linked glycans. These sugar chains do not decorate the barrier. They *are* the barrier. Their structure determines whether the mucus layer hydrates properly, repels microbes, resists proteolysis, and behaves as the immune-modulating surface it is meant to be. Defective glycosylation can produce abundant mucus that nevertheless fails to protect.
The architecture
Each MUC2 monomer carries dense clusters of O-glycans on its central PTS (proline-threonine-serine) domains. These glycans extend perpendicular to the protein backbone in what is called a bottle-brush structure. The configuration shields the peptide from proteolysis and gives the molecule its capacity to form the hydrated gel that constitutes the inner colonic mucus layer (https://pubmed.ncbi.nlm.nih.gov/32747752/" target="_blank" rel="noopener noreferrer" title="Open PMID:32747752 on PubMed/PMC">PMID:32747752).
Three terminal modifications govern function. Sulfation gives mucus its strong negative charge, increases hydration, and resists microbial proteolysis. Loss of sulfation has been shown to increase microbial infiltration and inflammation in animal models. Fucosylation is controlled by FUT2 in the gut. The H antigen and Lewis blood group antigens on mucin are fucose-dependent. About 20% of Europeans are FUT2 non-secretors. Non-secretor status is associated with increased Crohn's disease risk. Sialylation terminates many glycan chains. Sialic acid is also a substrate for specific bacteria — notably *Ruminococcus gnavus*, which can liberate it from MUC2 and consume it, expanding in IBD-associated dysbiosis.
What goes wrong
In ulcerative colitis, mucin glycan chains shorten and lose terminal sulfation. The mucus thins. In Crohn's disease, fucosylation drops markedly and immature Tn/sTn antigens appear — structures that immune lectins read as inflammatory signals.
In some patients with hypersecretory phenotypes, the mucus is abundant but poorly assembled. ER stress in goblet cells produces misfolded MUC2 that paradoxically secretes more while protecting less. The mechanism is being mapped; the clinical phenotype is sometimes described as "sticky mucus" or, in advanced cases, the formation of long mucus casts.
How to measure it
Standard histology shows mucus but not its structure. To characterize glycosylation: lectin histochemistry on biopsies (HPA for GalNAc, UEA-1 for fucose, MAL-II for sialic acid); NanoLC-MS/MS of biopsy mucin (research labs, e.g., Hansson group, Gothenburg); fecal sialic acid measurement as an indirect marker; FUT2 genotyping (rs601338) for secretor status — a simple SNP test.
What modulates it
Established and emerging interventions that affect mucin glycosylation include the gut microbiota itself (germ-free animals show altered glycan profiles), butyrate (supports goblet cell mucin production), and dietary fiber (substrate for the microbes that influence the system). Diet emulsifiers including carboxymethylcellulose and polysorbate-80 have been shown in animal and humanized models to disrupt mucus structure and permeability.
Open questions
What initiates goblet cell hypersecretion in non-inflamed mucosa? At what point does abundant defective mucus become more harmful than helpful? Can we measure mucin glycosylation status non-invasively at scale? These are not rhetorical. They are tracked questions, updated as the field moves.